TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement in Hamilton Anxiety Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Oxygen saturation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean HBL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: reduction in the level of haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tramadol requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in UBT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recovery time of renal impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum SCr levels restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary mAlb and beta2-MG levels restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in electrical skin impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet TXB2 release inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary 2,3-dinor-TXB2 excretion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: agitation/aggression score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hallucinations score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of nonunion cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: violent sexual behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in LTPA response efficacy and intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive processing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Arterio-venous concentration differences of glutamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-body glutamine rate of appearance (R(a))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual field performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: IOP changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: blood flow volume after passive hallux adduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of 20 Hz rTMS on EF deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accumulation of deep sleep before LH pulse onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of transitions between NREM, REM, and wake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average length of deep sleep episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subconjunctival bleb development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Rate of injection-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Development of venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in VIP levels after histamine challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in SP levels after allergen challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical reactions to allergen challenges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite primary end-point event
Endpoint domain: Mortality/survival
Primary endpoint: Mean injury severity score for admitted patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay for admitted patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Activated clotting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-factor Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total graft failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Moderate pain at 10 days postoperatively
Endpoint domain: Adverse events/effects
Primary endpoint: Weight gain between 8 mo and 2 y
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pap test completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of residual root filling material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apical patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain scores at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women requesting postoperative opioids
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of IL‐1β, IL‐6, CXCL8, and CCL3 in MLF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ICAM‐1 mRNA levels in nasal curettage specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutrophil levels in nasal lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Forced expiratory flow at 25% (FEF25)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CO diffusion lung/alveolar volume (DLCO/VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: tHcy and tCys concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endometrial hyperplasia or endometrial cancer risk
Endpoint domain: Adverse events/effects
Primary endpoint: relief of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cmax of mometasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of mometasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of treatment-emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative immune rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reliability of predictive procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secretory units of islets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Agreement in detecting cervical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of CIN 2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: FTA precision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: VLDL lag time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of suicidal ideation
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of non-suicidal self-injury
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of self-injury ideation
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum concentration in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from 0 to 9 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (grade 1 fatigue and anorexia)
Endpoint domain: Adverse events/effects
Primary endpoint: Hand sanitization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in PANSS total score for negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in PANSS total score for general psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of tardive dyskinesia (TD)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of prostate-specific antigen level < 0.2 ng/mL at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver confidence in caregiving situations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived preparedness to provide care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy in caregiver role
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-rated performance in daily use of the paretic upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bleeding/spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain coping skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bronchial wall thickening (BWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary concentration of HNP1-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary secretion rates of HNP1-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution time of whitening reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fading of tattoos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reductions in psychic symptoms of the HAM-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological measures of inhibitory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: driving capability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival with favorable neurologic outcome at day 90
Endpoint domain: Mortality/survival
Primary endpoint: percentage of mucosa visualized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: one-legged standing balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean percentage increase in CD3, CD19 and CD16 positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in MSCS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to significant improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total intestinal parasitic infections
Endpoint domain: Adverse events/effects
Primary endpoint: New Giardia infections
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients requiring rescue doses of fentanyl
Endpoint domain: Adverse events/effects
Primary endpoint: Patient satisfaction with sedation/analgesia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma E concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Parents' own parenting
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Fasting serum total cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial serum insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: core temperature increase rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean body (core) temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure Reduction Rate (IOP-RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioequivalence in rate and extent of drug absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posttreatment CAPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCL-S score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild Cognitive Impairment (MCI) prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Correction of angulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weekly intake of saturated fat
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Weekly intake of cholesterol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Radiographic abnormalities of bones and joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Traumatic fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Charcot changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of prescribing antibacterial therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Combined endpoint of death or hospital stays for HF
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in nighttime frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of detrusor overactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic disease or viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to CMV disease or viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of tissue-invasive infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: BMD (%) at zone 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD (%) at zone 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar BMD (%) anterior‐posterior (AP) side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition of cancer warning signs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: suppression of iPTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence of hyperphosphatemia
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement rate of eyes treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of lid ptosis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of raised intraocular pressure
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy for advanced fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in EF (Vita scale units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fNIRS activation in the left inferior frontal gyrus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: baseline corrected area under the curve values of HO‐1 mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baseline corrected area under the curve values of HO‐1 protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm birth prevention
Endpoint domain: Mortality/survival
Primary endpoint: relaxed elbow extension (joint angle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: creatine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unadjusted mortality at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: postprandial triglycerides (TGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Condylar resorptive changes greater than 1.5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: improvement in limb pain causes waking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in uncomfortable in bed due to immobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in difficulty dressing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: improvement in felt depressed
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement in difficulty getting around in public
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: total average costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Vocal intensity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain sensitivity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk flexion range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Removal from plasma of chylomicron and remnants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of pain on awakening
Endpoint domain: Adverse events/effects
Primary endpoint: Burnout rates
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: impact on cardiovascular disease risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients achieving more than 90% repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of patients experiencing 50% or greater repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Successful medical abortions
Endpoint domain: Mortality/survival
Primary endpoint: fluid absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cumulative complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Wound infection frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement on the pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for off-protocol rescue analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of pregnancies
Endpoint domain: Mortality/survival
Primary endpoint: Rate of good quality embryos at day 3 after fertilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pain level during dressing change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in selective memory processes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perception of memory function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Better vocational outcomes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: VAS pain summary scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean thyroid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: EC(50) concentration for propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EC(50) concentration for sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak VO2 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related quality of life (physical)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sensitivity of flow cytometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of mantle cell lymphoma cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of minimal residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to dependence and institutionalization
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Treatment failure (death or liver transplantation)
Endpoint domain: Mortality/survival
Primary endpoint: Histological stage progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cholestasis levels (alkaline phosphatase, gammaglutamyl transferase, alanine aminotransferase, cholesterol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes